Qun Chen 1 , 2 , Wu-Jun Wang 3 , Yun-Xuan Jia 2 , Hao Yuan 1 , 2 , Peng-Fei Wu 1 , 2 , Wan-Li Ge 1 , 2 , Ling-Dong Meng 1 , 2 , Xu-Min Huang 1 , 2 , Peng Shen 1 , 2 , Tao-Yue Yang 1 , 2 , Yi Miao 1 , 2 , Jing-Jing Zhang , 1 , 2 , Kui-Rong Jiang , 1 , 2
13 May 2021
Pancreatic tumors are classified into endocrine and exocrine types, and the clinical manifestations in patients are nonspecific. Most patients, especially those with pancreatic ductal adenocarcinoma (PDAC), have lost the opportunity to receive for the best treatment at the time of diagnosis. Although chemotherapy and radiotherapy have shown good therapeutic results in other tumors, their therapeutic effects on pancreatic tumors are minimal. A multifunctional transcription factor, Yin-Yang 1 (YY1) regulates the transcription of a variety of important genes and plays a significant role in diverse tumors. Studies have shown that targeting YY1 can improve the survival time of patients with tumors. In this review, we focused on the mechanism by which YY1 affects the occurrence and development of pancreatic tumors. We found that a YY1 mutation is specific for insulinomas and has a role in driving the degree of malignancy. In addition, changes in the circadian network are a key causative factor of PDAC. YY1 promotes pancreatic clock progression and induces malignant changes, but YY1 seems to act as a tumor suppressor in PDAC and affects many biological behaviors, such as proliferation, migration, apoptosis and metastasis. Our review summarizes the progress in understanding the role of YY1 in pancreatic endocrine and exocrine tumors and provides a reasonable assessment of the potential for therapeutic targeting of YY1 in pancreatic tumors.